Eiger InnoTherapeutics

InnoTherapeutics is a clinical-stage biotechnology company focused on the development and commercialization of Peginterferon lambda, a first-in-class type III interferon. The company acquired the global rights to the asset from Eiger BioPharmaceuticals in 2024 following a bankruptcy-related asset sale. Peginterferon lambda is currently in Phase 3 clinical trials for the treatment of chronic Hepatitis D Virus (HDV) infection, where it has demonstrated the potential to provide antiviral activity with a more favorable tolerability profile than traditional type I interferons. By targeting the type III interferon receptor, which has a more restricted tissue distribution, the therapy aims to minimize systemic side effects. InnoTherapeutics is dedicated to bringing this orphan drug to market to address the significant unmet needs of patients with chronic viral hepatitis.